Bristol-Myers Squibb Co

Bristol-Myers Squibb develops and commercializes prescription pharmaceuticals treating cancer, cardiovascular disease, immunology disorders, and fibrosis. The company generates revenue from proprietary drugs including Eliquis for blood clot prevention, Opdivo for cancer immunotherapy, and Revlimid for blood cancers. Research focuses on small molecule drugs and biological therapies addressing unmet medical needs. Bristol-Myers markets products globally through sales representatives calling on oncologists, cardiologists, and hospitals.

Bristol-Myers Squibb offers high cash flow generation from blockbuster drugs with patent protection. The company pays an attractive dividend yield and invests heavily in clinical trials for pipeline development. Risks include patent expirations on major revenue contributors like Revlimid, clinical trial failures, and pricing pressure from government negotiations. The stock trades at discounted valuations reflecting concerns about replacing maturing products.

Merck competes directly in cancer immunotherapy with Keytruda challenging Opdivo. Pfizer contests in cardiovascular drugs and oncology. Johnson & Johnson competes across multiple therapeutic areas including immunology. AbbVie challenges in immunology with Rinvoq and Skyrizi, while Amgen competes in oncology and cardiovascular disease treatment.

Bristol-Myers Squibb has maintained uninterrupted quarterly dividends for decades with a moderate payout ratio. The company prioritizes dividend sustainability and has continued payments through major acquisitions like Celgene. Dividend growth has been modest as the company balances shareholder returns with R&D investments and debt reduction.

BMY last closed at $58.94, up 2.70% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $42.52 and a high of $62.89. The current price represents 81% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 36 analysts covering BMY, the consensus rating is Hold — 15 rate it a buy, 19 hold, and 2 sell. The average price target sits at $174.50, implying 196% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Bristol-Myers Squibb Co generated $47.94B in revenue during fiscal year 2026, with $7.02B reaching the bottom line as net income. The net profit margin of 14.6% is solid for its sector.

BMY trades at a P/E ratio of 16.52 on trailing earnings of $3.46 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +7.87% (3M), +33.50% (6M), -0.46% (1Y), +10.25% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether BMY is outperforming or lagging the broader market.